我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300357 我武生物

已收盘 09-03 15:00:00

{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":22.55,"timestamp":1788419019000,"preClose":22.8,"halted":0,"volume":4794758,"delay":0,"changeRate":-0.011,"floatShares":484999999,"shares":524000000,"eps":0.7972,"marketStatus":"已收盘","change":-0.25,"latestTime":"09-03 15:00:00","open":22.82,"high":22.93,"low":22.5,"amount":109000000,"amplitude":0.0189,"askPrice":22.55,"askSize":57,"bidPrice":22.54,"bidSize":374,"shortable":0,"etf":0,"ttmEps":0.7972,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.8,"symbolType":"stock","openAndCloseTimeList":[[1788399000000,1788406200000],[1788411600000,1788418800000]],"highLimit":25.08,"lowLimit":20.52,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":4.33,"roa":"--","peRate":28.286503,"roe":"7.87%","epsLYR":0.7276,"committee":0.73028,"marketValue":11807000000,"turnoverRate":0.0099,"status":1,"floatMarketCap":10946000000},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"2664583458","title":"西南证券：给予我武生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664583458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664583458?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:08","pubTimestamp":1788257308,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对我武生物进行研究并发布了研究报告《2026半年报点评：黄花蒿滴剂延续高增，收入稳健增长》，给予我武生物买入评级。公司核心产品收入稳健增长，黄花蒿滴剂贡献新的收入增量，研发管线有序推进，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。)本文数据来源于西南证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100032381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663028138","title":"【机构调研记录】浙商基金调研我武生物、伟思医疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2663028138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663028138?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:03","pubTimestamp":1788134630,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月28日披露的机构调研信息，浙商基金近期对2家上市公司进行了调研，相关名单如下：1）我武生物 调研纪要：公司上半年营收和利润受到增值税政策调整影响，粉尘螨滴剂等产品税率由3%升至13%，叠加去年同期高基数，增速有所放缓。浙商基金成立于2010年，截至目前，资产管理规模254.44亿元，排名115/212；资产管理规模197.56亿元，排名110/212；管理公募基金数76只，排名83/212；旗下公募基金经理13人，排名97/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100002156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","688580","BK0251","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706040","title":"开源证券：给予我武生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662706040?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:54","pubTimestamp":1787918084,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,阮帅近期对我武生物进行研究并发布了研究报告《公司信息更新报告：2026上半年稳健增长，黄花蒿花粉滴剂快速放量》，给予我武生物买入评级。最新盈利预测明细如下：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。)本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800048321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066233","title":"我武生物(300357)6月30日股东户数3.53万户，较上期减少0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066233","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066233?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:52","pubTimestamp":1787910755,"startTime":"0","endTime":"0","summary":"证券之星消息，近日我武生物披露，截至2026年6月30日公司股东户数为3.53万户，较3月31日减少309.0户，减幅为0.87%。在生物制品行业个股中，我武生物股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.54万户。从股价来看，2026年3月31日至2026年6月30日，我武生物区间跌幅为9.19%，在此期间股东户数减少309.0户，减幅为0.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662087204","title":"图解我武生物中报：第二季度单季净利润同比下降8.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662087204","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662087204?lang=zh_cn&edition=full","pubTime":"2026-08-28 02:44","pubTimestamp":1787856250,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物2026年中报显示，上半年度公司主营收入5.14亿元，同比上升6.18%；归母净利润2.13亿元，同比上升20.59%；扣非净利润1.83亿元，同比上升6.05%；其中2026年第二季度，公司单季度主营收入2.61亿元，同比上升2.17%；单季度归母净利润9421.96万元，同比下降8.23%；单季度扣非净利润9368.81万元，同比下降5.34%；负债率7.71%，投资收益2903.26万元，财务费用-872.28万元，毛利率95.29%。财报数据概要请见下图:本文数据来源于我武生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800006041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662787315","title":"我武生物：将持续加大“黄花蒿花粉变应原舌下滴剂”（商品名","url":"https://stock-news.laohu8.com/highlight/detail?id=2662787315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662787315?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:48","pubTimestamp":1787647693,"startTime":"0","endTime":"0","summary":"公司将持续加大“黄花蒿花粉变应原舌下滴剂”的推广力度。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。过敏原特异性免疫治疗 ，即脱敏治疗，是世界卫生组织推荐的唯一可能影响过敏性疾病自然进程的“对因治疗”方法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500034104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661261318","title":"我武生物最新公告：获得猫毛膜剂药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261318","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661261318?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:50","pubTimestamp":1787305818,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司从国家药品监督管理局政务服务门户网站下载获得《药物临床试验批准通知书》，由公司提交的“猫毛膜剂”药物临床试验申请获得批准。截至公告披露日，尚未有其他企业取得该品种的《药品注册证书》。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660098400","title":"我武生物：公司未采用您提及的模型设计药物候选分子","url":"https://stock-news.laohu8.com/highlight/detail?id=2660098400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660098400?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:36","pubTimestamp":1787218569,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物08月20日在投资者关系平台上答复投资者关心的问题。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660734402","title":"8月20日我武生物涨6.97%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660734402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660734402?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:42","pubTimestamp":1787215351,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日我武生物涨6.97%创60日新高，收盘报25.95元，换手率7.02%，成交量33.98万手，成交额8.95亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为14.15亿元，最新净值1.6784，较上一交易日下跌2.5%，近一年下跌14.22%。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","BK1161","BK0239","300357","BK0028","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660477214","title":"创新药迎新政策利好，我武生物大涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477214","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660477214?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:43","pubTimestamp":1787193798,"startTime":"0","endTime":"0","summary":"8月20日，创新药板块大幅高开，相关概念股强势拉升，我武生物一度涨近12%。消息面上，创新药迎来新的政策利好。业内人士指出，《规划》的核心思路是从“单纯控费”转向“战略购买”，在保基本底线不变的同时，给高质量创新留出明确政策空间。这意味着创新药赛道将迎来新的政策利好，集采进入“规范化优化”新阶段，细分赛道由此打开全新增量空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026082000013980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK1161","BK0239","06978","BK0028","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660427161","title":"股市必读：我武生物（300357）8月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660427161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660427161?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:51","pubTimestamp":1787161872,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，我武生物报收于24.26元，下跌1.82%，换手率2.11%，成交量10.2万手，成交额2.49亿元。董秘最新回复投资者： 请问公司什么时候公布业绩预告？董秘： 投资者您好，公司2026年半年度具体经营情况请关注公司后续披露的2026年半年度报告。当日关注点交易信息汇总：8月19日主力资金净流出989.58万元，占总成交额3.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659136293","title":"创新药板块延续强势，我武生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659136293","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659136293?lang=zh_cn&edition=full","pubTime":"2026-08-13 14:31","pubTimestamp":1786602665,"startTime":"0","endTime":"0","summary":"8月13日，创新药板块延续强势，我武生物盘中一度涨超5%。消息面上，近期创新药有多重利好共振。医药魔方数据显示，上半年中国创新药企共披露123笔BD交易，同比增长24.24%；首付款合计逾49.75亿美元，同比增长71.65%。国家药品监督管理局口径下，上半年对外授权共达成81笔合作，交易总额约1100亿美元，已达2025年全年总额的80%。近日，我武生物自主研发的化学1类新药S01D片临床试验申请已获国家药品监督管理局受理，拟用于耐药肺结核成人患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081300019420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","159992","06978","BK1574","300357","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658964054","title":"创新药概念持续走强，我武生物涨近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658964054?lang=zh_cn&edition=full","pubTime":"2026-08-11 13:56","pubTimestamp":1786427794,"startTime":"0","endTime":"0","summary":"8月11日，创新药概念盘中持续走强，我武生物一度涨近4%，触及25.98元/股。中泰证券表示，2026年以来，中国创新药产业逐步进入价值兑现阶段，行业逻辑由过去依赖BD事件催化，转向海外商业化、临床数据兑现及持续收入贡献，近期海外龙头药企财报持续验证中国创新资产价值，MNC对于中国创新药的战略定位逐渐提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081100018659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK0239","300357","06978","BK1574","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670713","title":"股市必读：我武生物新发布《关于获得S01D片药物临床试验申请受理通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670713?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:50","pubTimestamp":1786297820,"startTime":"0","endTime":"0","summary":"公司公告汇总：我武生物S01D片药物临床试验申请获国家药监局受理，为化学药品1类，拟用于耐药肺结核成人患者治疗，目前国内外尚无相同化学药物获批上市。公司公告汇总关于获得S01D片药物临床试验申请受理通知书的公告浙江我武生物科技股份有限公司收到国家药品监督管理局出具的《受理通知书》，S01D片药物临床试验申请已获受理。药品审评中心将在受理后六十日内决定是否同意开展临床试验，逾期未通知视为同意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161966","title":"8月7日我武生物涨6.10%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657161966?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:48","pubTimestamp":1786092510,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日我武生物涨6.10%，收盘报24.88元，换手率3.86%，成交量18.66万手，成交额4.51亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为14.15亿元，最新净值1.5941，较上一交易日下跌0.96%，近一年下跌15.71%。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK0028","BK1574","300357","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657154836","title":"我武生物：公司始终聚焦主业，完善变应原制品产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2657154836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657154836?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:33","pubTimestamp":1786091604,"startTime":"0","endTime":"0","summary":"AI赋能上，其类脑算法、AI医生等技术是否反哺主营，协同效应怎样？希望管理层厘清从AI研发到效益转化的路径，谢谢！公司始终聚焦主业，完善变应原制品产品管线，深耕过敏性疾病诊疗领域，并逐步推动在干细胞药物、天然药物等其他领域的研发工作。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542794","title":"我武生物：猫毛膜剂药物临床试验申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657542794?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:51","pubTimestamp":1785934290,"startTime":"0","endTime":"0","summary":"2026年6月，由公司提交的“猫毛膜剂”药物临床试验申请已获得正式受理，其给药方式为舌下含服，剂型为膜剂。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884888","title":"股市必读：我武生物（300357）7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655884888?lang=zh_cn&edition=full","pubTime":"2026-07-29 02:03","pubTimestamp":1785261797,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，我武生物报收于23.17元，下跌1.4%，换手率1.17%，成交量5.67万手，成交额1.32亿元。公司公告汇总：子公司“人脐带间充质干细胞II型注射液”临床试验申请获国家药监局正式受理，注册分类为治疗用生物制品1类，适应症为脓毒症和（或）脓毒性休克，目前国内外尚无同类获批上市产品。近日，该申请已获国家药品监督管理局正式受理。目前国内外尚无同类获批上市产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900001345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654008156","title":"我武生物最新公告：子公司人脐带间充质干细胞II型注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2654008156","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654008156?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:52","pubTimestamp":1785232337,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司间接控股子公司浙江我武干细胞科技有限公司提交的“人脐带间充质干细胞II型注射液”药物临床试验申请已获国家药品监督管理局正式受理，适应症为脓毒症和(或)脓毒性休克。该药品为治疗用生物制品1类，后续需经审评、临床试验及上市许可等环节，结果存在不确定性。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。)以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800029315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650990754","title":"股市必读：我武生物（300357）7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650990754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650990754?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:22","pubTimestamp":1783531330,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，我武生物报收于23.15元，上涨1.09%，换手率1.7%，成交量8.23万手，成交额1.9亿元。目前，针对脓毒症和脓毒性休克的治疗策略主要局限于支持性治疗与广谱抗菌药物的应用。尽管液体复苏、血管活性药物及器官功能支持技术不断进步，但脓毒症和脓毒性休克患者的病死率及远期并发症发生率仍居高不下，临床层面仍亟待突破性治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788459913945,"stockEarnings":[{"period":"1week","weight":-0.0347},{"period":"1month","weight":-0.0713},{"period":"3month","weight":0.0205},{"period":"6month","weight":-0.0759},{"period":"1year","weight":-0.3011},{"period":"ytd","weight":-0.1968}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35260人(较上一季度减少0.87%)","perCapita":"13766股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":"　　浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒等系列点刺液产品。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}